New combo aims to tackle returning blood cancer

NCT ID NCT07024706

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This phase 2 trial tests a combination of two drugs, acalabrutinib and venetoclax, in 80 people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer has returned after initial treatment. Participants must have responded well to their first therapy and stayed in remission for at least two years. The study aims to see if this finite-duration combo can effectively control the disease again.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: acalabrutinib and venetoclax
What this could lead to: If successful, this could offer a new treatment option for people with CLL/SLL whose cancer returns after initial therapy, potentially extending remission without continuous medication.
What could go wrong: This is a small, early-phase study (80 people) with no results yet. The treatment may not work as well as hoped, and side effects like low blood counts or infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) SMALL LYMPHOCYTIC LYMPHOMA (SLL)

Contacts and locations

Locations

Research Site
RECRUITING

Boston, Massachusetts, 02215, United States
Research Site
WITHDRAWN

Charlotte, North Carolina, 28204, United States
Research Site
RECRUITING

Charlotte, North Carolina, 28204, United States
Research Site
RECRUITING

Durham, North Carolina, 27705, United States
Research Site
RECRUITING

Winston-Salem, North Carolina, 27103, United States
Research Site
RECRUITING

Horn, 3580, Austria
Research Site
NOT_YET_RECRUITING

Goiânia, 74605-020, Brazil
Research Site
NOT_YET_RECRUITING

Porto Alegre, 90035-903, Brazil
Research Site
NOT_YET_RECRUITING

Porto Alegre, 90110-270, Brazil
Research Site
NOT_YET_RECRUITING

São Paulo, 01246-000, Brazil
Research Site
NOT_YET_RECRUITING

São Paulo, 1409, Brazil
Research Site
NOT_YET_RECRUITING

Brno, 625 00, Czechia
Research Site
NOT_YET_RECRUITING

Hradec Kralova, 50005, Czechia
Research Site
NOT_YET_RECRUITING

Ostrava, 708 502, Czechia
Research Site
RECRUITING

Dublin, 7, Ireland
Research Site
RECRUITING

Dublin, D08 NHY1, Ireland
Research Site
RECRUITING

Meldola, 47014, Italy
Research Site
WITHDRAWN

Milan, 20132, Italy
Research Site
NOT_YET_RECRUITING

Milan, 20162, Italy
Research Site
RECRUITING

Padua, 35128, Italy
Research Site
RECRUITING

Ravenna, 48121, Italy
Research Site
WITHDRAWN

Rome, 00168, Italy
Research Site
WITHDRAWN

Torino, 10126, Italy
Research Site
NOT_YET_RECRUITING

Bydgoszcz, 85-168, Poland
Research Site
WITHDRAWN

Krakow, 30-727, Poland
Research Site
WITHDRAWN

Lodz, 93-513, Poland
Research Site
NOT_YET_RECRUITING

Lublin, 20-090, Poland
Research Site
NOT_YET_RECRUITING

Warsaw, 02-172, Poland
Research Site
NOT_YET_RECRUITING

Warsaw, 02-776, Poland
Research Site
RECRUITING

Barcelona, 08041, Spain
Research Site
NOT_YET_RECRUITING

Barcelona, 8035, Spain
Research Site
RECRUITING

Granada, 18014, Spain
Research Site
RECRUITING

Madrid, 28031, Spain
Research Site
RECRUITING

Madrid, 28034, Spain
Research Site
NOT_YET_RECRUITING

Madrid, 28041, Spain
Research Site
RECRUITING

Majadahonda, 28222, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.